血制品储存时间的长短是**影响输血效果的因素么?

2015-12-06 QQduhq 译 MedSci原创

输血这一治疗方法已经存在一个世纪之久,每年全球患者将输注约1亿单位的红细胞(RBC)。输血的治疗作用除了用以补给血量,维持血容量,提高血压以抗休克和防止出血性休克等,还可供给具有带氧能力的红细胞以纠正因红细胞减少或其带氧能力降低所导致的急性缺氧症;补充各种凝血因子以纠正某些病人血液凝固障碍。如急性大失血,引起血压下降时,则应输全血。严重贫血者由于红细胞数量不足,而总血量不一定少,故最好输以浓缩的红

输血这一治疗方法已经存在一个世纪之久,每年全球患者将输注约1亿单位的红细胞(RBC)。输血的治疗作用除了用以补给血量、维持血容量、提高血压以抗休克和防止出血性休克等,还可纠正因红细胞减少或其带氧能力降低所导致的急性缺氧症,纠正血液凝固障碍。如:急性大失血引起血压下降时,则应输全血;严重贫血者由于红细胞数量不足,而总血量不一定少,故最好输以浓缩的红细胞悬液;患大面积烧伤的病人,主要是血浆减少,最好输以血浆或血浆代用品;对某些出血性疾病的患者,则可输入浓缩的血小板悬液或含有凝血因子的血浆以增强凝血能力促进止血。


输血能使贫血迅速减轻以至完全得到纠正,虽然它的效果仅是暂时的,但仍然是贫血对症治疗中最重要的措施。输血绝非有益无害,严重的输血反应可以致命。故必须严格掌握输血的适应证,无明确适应证者不应滥用输血。

尽管输血导致民众出现传染病的风险已大幅降低,但仍会出现免疫失调、血管调节障碍和凝血功能障碍等问题。全球统一规定,红细胞可在2-6°C条件下储存42天(基于红细胞表面的比例保持在24小时循环输血后健康的接受者和溶血的程度)。 

普遍认为,导致输注的红细胞疗效和安全性出现问题的原因在于“存储病变”(用于描述储存红细胞出现的变化如红细胞变形性和DPG及三磷酸腺苷浓度降低)。存储时间延长也会导致还原型烟酰胺腺嘌呤二核苷酸磷酸(NADPH)及谷胱甘肽含量降低,这可能导致细胞出现氧化损伤、红细胞膜微粒增多、溶血增加,并降低一氧化氮的可用性。红细胞在存储过程中出现存储病变,这使得人们认为输血质量与病人的病情和死亡率等有关。
 
Dhabangi教授及同事对乌干达290名严重贫血的患儿随机分组,分别接受储存时间短的血细胞(少于10天)和储存时间长的血细胞(25-35天),结果表明血细胞储存时间的长短并不影响其降低血乳酸的水平(8h内)。该研究发表在最新一期的JAMA上(点击查看详细)。

考虑到该实验仅针对患有严重贫血的乌干达患儿,因此该结果是否对其他地区的儿童也适用?同时,该研究中的患儿大多数患有疟疾或镰状细胞病,因此对于未患这两种疾病的严重贫血患儿是否可同样适用?患儿如此,对于成人是否也同样如此呢?以上这些通过该研究均不得而知,此外,该研究并未涉及患儿输血后免疫功能的差异以及输血后是否感染相关血液型传播疾病。因此,研究人员需要进一步开展研究。

研究人员认为,其他因素如献血者的性别、年龄、ABO血型、Rh类型及献血频率等也会有一定的影响。已经有研究表明,献血者的年龄和性别与红细胞脆性和输血后出现溶血有关。此外,献血者的遗传因素将影响储存血红细胞表面氧化损伤的易感性。红细胞的采集和血制品的分离等也会影响红细胞质量。

如果不能根据血制品的储存时间评估红细胞质量,则需要更精确数据来评估,一些生化指标如患者的血红蛋白或红细胞比容、出现溶血的发生率、pH、乳酸、电解质、2,3-DPG等都可反应输注红细胞的质量。一些生物指标也直接影响输血的有效性和安全性、如红细胞可变形性和脆性对输注的红细胞质量也至关重要。

随着越来越多的研究证明献血者的个人因素及其血液成分对输注红细胞质量的影响,研究人员认为,不能仅凭储存时间的长短评估血液制品的性能和对疾病的治疗效果。因此,血站和医院等血液采集场所需要收集献血者的个人信息及其血液相关指标。同时,医院对于受血者也应记录下相关信息,如输血指征、输血类别和剂量、患者出现的相关生理反应和输血不良事件的发生率等信息,以便更好地救治患者。

原始出处:

Philip C. Spinella, MD, FCCM1; Jason Acker,Storage Duration and Other Measures of Quality of Red Blood Cells for Transfusion,JAMA,5,Dec,2015

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2009822, encodeId=e61a2009822a1, content=<a href='/topic/show?id=48e58892623' target=_blank style='color:#2F92EE;'>#血制品#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88926, encryptionId=48e58892623, topicName=血制品)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Thu Aug 25 14:00:00 CST 2016, time=2016-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=77725, encodeId=fa47e772510, content=好文章,值得收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73441710184, createdName=明崖, createdTime=Wed Apr 13 21:39:00 CST 2016, time=2016-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48879, encodeId=cf09488e90f, content=好文章,值得收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sun Dec 27 08:27:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48880, encodeId=dd8d4888061, content=好文章,值得收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sun Dec 27 08:27:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259645, encodeId=43ab1259645c7, content=<a href='/topic/show?id=569c9382389' target=_blank style='color:#2F92EE;'>#输血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93823, encryptionId=569c9382389, topicName=输血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Tue Dec 08 00:00:00 CST 2015, time=2015-12-08, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2009822, encodeId=e61a2009822a1, content=<a href='/topic/show?id=48e58892623' target=_blank style='color:#2F92EE;'>#血制品#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88926, encryptionId=48e58892623, topicName=血制品)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Thu Aug 25 14:00:00 CST 2016, time=2016-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=77725, encodeId=fa47e772510, content=好文章,值得收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73441710184, createdName=明崖, createdTime=Wed Apr 13 21:39:00 CST 2016, time=2016-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48879, encodeId=cf09488e90f, content=好文章,值得收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sun Dec 27 08:27:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48880, encodeId=dd8d4888061, content=好文章,值得收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sun Dec 27 08:27:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259645, encodeId=43ab1259645c7, content=<a href='/topic/show?id=569c9382389' target=_blank style='color:#2F92EE;'>#输血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93823, encryptionId=569c9382389, topicName=输血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Tue Dec 08 00:00:00 CST 2015, time=2015-12-08, status=1, ipAttribution=)]
    2016-04-13 明崖

    好文章,值得收藏

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2009822, encodeId=e61a2009822a1, content=<a href='/topic/show?id=48e58892623' target=_blank style='color:#2F92EE;'>#血制品#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88926, encryptionId=48e58892623, topicName=血制品)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Thu Aug 25 14:00:00 CST 2016, time=2016-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=77725, encodeId=fa47e772510, content=好文章,值得收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73441710184, createdName=明崖, createdTime=Wed Apr 13 21:39:00 CST 2016, time=2016-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48879, encodeId=cf09488e90f, content=好文章,值得收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sun Dec 27 08:27:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48880, encodeId=dd8d4888061, content=好文章,值得收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sun Dec 27 08:27:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259645, encodeId=43ab1259645c7, content=<a href='/topic/show?id=569c9382389' target=_blank style='color:#2F92EE;'>#输血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93823, encryptionId=569c9382389, topicName=输血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Tue Dec 08 00:00:00 CST 2015, time=2015-12-08, status=1, ipAttribution=)]
    2015-12-27 hixiaoluo

    好文章,值得收藏

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2009822, encodeId=e61a2009822a1, content=<a href='/topic/show?id=48e58892623' target=_blank style='color:#2F92EE;'>#血制品#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88926, encryptionId=48e58892623, topicName=血制品)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Thu Aug 25 14:00:00 CST 2016, time=2016-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=77725, encodeId=fa47e772510, content=好文章,值得收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73441710184, createdName=明崖, createdTime=Wed Apr 13 21:39:00 CST 2016, time=2016-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48879, encodeId=cf09488e90f, content=好文章,值得收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sun Dec 27 08:27:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48880, encodeId=dd8d4888061, content=好文章,值得收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sun Dec 27 08:27:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259645, encodeId=43ab1259645c7, content=<a href='/topic/show?id=569c9382389' target=_blank style='color:#2F92EE;'>#输血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93823, encryptionId=569c9382389, topicName=输血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Tue Dec 08 00:00:00 CST 2015, time=2015-12-08, status=1, ipAttribution=)]
    2015-12-27 hixiaoluo

    好文章,值得收藏

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2009822, encodeId=e61a2009822a1, content=<a href='/topic/show?id=48e58892623' target=_blank style='color:#2F92EE;'>#血制品#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88926, encryptionId=48e58892623, topicName=血制品)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Thu Aug 25 14:00:00 CST 2016, time=2016-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=77725, encodeId=fa47e772510, content=好文章,值得收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73441710184, createdName=明崖, createdTime=Wed Apr 13 21:39:00 CST 2016, time=2016-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48879, encodeId=cf09488e90f, content=好文章,值得收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sun Dec 27 08:27:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48880, encodeId=dd8d4888061, content=好文章,值得收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sun Dec 27 08:27:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259645, encodeId=43ab1259645c7, content=<a href='/topic/show?id=569c9382389' target=_blank style='color:#2F92EE;'>#输血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93823, encryptionId=569c9382389, topicName=输血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Tue Dec 08 00:00:00 CST 2015, time=2015-12-08, status=1, ipAttribution=)]
    2015-12-08 windight

相关资讯

网织红细胞**值计算公式

网织红细胞绝对值计算公式

STS 2015:CABG时输血增加肺炎风险

2015年美国心胸外科学会(STS)年会上的一项研究数据显示,单独的冠状动脉旁路移植术(CABG)中或之后输注红细胞的患者,术后发生肺炎风险增加。 密歇根大学健康系统 Donald S. Likosky博士指出,“CABG后肺炎是已知的危险,且肺炎可增加患者的发病和死亡风险。既往研究已表明,每20例接受CABG的患者就有1例发生主要感染,而肺炎是最常见类型的感染。” 该研究于201

NEJM:红细胞存储时间对心脏手术病人或无影响

背景 一些观察研究报道,已存储超过2至3周的红细胞输血与严重的,甚至是致命的,不良事件有关。接受心脏手术患者可能特别易受输血的不利影响。 方法 我们从2010年到2014年在多个站点进行了一项随机试验。参与者为12岁或以上的处于复杂的心脏手术,并可能接受输血红细胞的人,他们被随机分配去接受白细胞红细胞保存10天或更短(短期存储组)或21天或更长(长期存储组)为术中及术后输血。主要结果是在多器官功

JAMA:红细胞储存时间的长短与其携氧能力的关系

贫血儿童由于乳酸水平较高经常出现酸中毒。该研究的目的是确定输注长期保存的红细胞单位同储存时间较短的红细胞后,对减少严重贫血儿童血液中乳酸含量和改善脑组织氧饱和度的区别。研究表明,红细胞保存时间的长短对降低血乳酸水平并无明显区别。这些发现对治疗缺氧和乳酸酸中毒的贫血患儿有重要影响。

PNAS:红细胞可作为全身给药载体

当红细胞穿越血管时,它们将氧气传递到你身体几乎每一个角落和空隙。但是氧气并不是它们能携带的唯一东西。目前,麻省理工学院一个研究小组通过设计红血细胞,使其表面具有“粘性”蛋白质,赋予这些细胞携带任何东西的能力,从治疗免疫系统疾病或癌症的药物,到用于血管成像的放射性分子。相关研究结果发表在6月30日的PNAS杂志。 宾夕法尼亚大学的生物化学家Vladimir Muzykantov没有参与这项新工作,

JAMA:接受心脏手术的患者是否应接受储存血液成分?

在一些大型手术中,患者通常要输注一些红细胞以弥补丢失的血液成分。然而,对于要进行心脏手术的患者,是否应该为其输注储存较久的血液成分,研究人员争执不休。瑞典卡罗林斯卡医学院研究人员进行的一项发表在JAMA的研究表明,储存在14-42天之间的血液成分都可安全使用。 血中红细胞最久储存时长为42天,但一般为术中患者输注的红细胞储存时长平均是18天。红细胞在血液循环中携带氧气,并为全身供氧。若储存时间较久